Long-term In Vitro Treatment of Human Glioblastoma Cells with Temozolomide Increases Resistance In Vivo through Up-regulation of GLUT Transporter and Aldo-Keto Reductase Enzyme AKR1C Expression
Glioblastoma (GBM) is the most frequent malignant glioma. Treatment of GBM patients is multimodal with maximum surgical resection, followed by concurrent radiation and chemotherapy with the alkylating drug temozolomide (TMZ). The present study aims to identify genes implicated in the acquired resis...
Main Authors: | Benjamin Le Calvé, Michal Rynkowski, Marie Le Mercier, Céline Bruyère, Caroline Lonez, Thierry Gras, Benjamin Haibe-Kains, Gianluca Bontempi, Christine Decaestecker, Jean-Marie Ruysschaert, Robert Kiss, Florence Lefranc |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2010-09-01
|
Series: | Neoplasia: An International Journal for Oncology Research |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1476558610800740 |
Similar Items
-
Long-term Temozolomide Treatment Induces Marked Amino Metabolism Modifications and an Increase in TMZ Sensitivity in Hs683 Oligodendroglioma Cells
by: Delphine Lamoral-Theys, et al.
Published: (2010-01-01) -
Aldo-keto reductase (AKR) superfamily: Genomics and annotation
by: Mindnich Rebekka D, et al.
Published: (2009-07-01) -
Expression of the Aldo-Keto Reductases AKR1B1 and AKR1B10 in Human Cancers.
by: Brian eLaffin, et al.
Published: (2012-06-01) -
Murine Aldo-Keto Reductases: Identification of AKR1B8 as an ortholog of human AKR1B10
by: Rajput, Sandeep
Published: (2009) -
Functional Analysis of Aldo-keto Reductase 5(OsAKR5) genes in Rice
by: Ling Yang, et al.